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Randomised controlled trial of hydroquinine in muscle cramps
P H P Jansen , K C W Veenhuizen, A f M W esseling, Th de Boo, A L M Verbeek
Summary
Background A lthough qu in ine and hydroquin ine are 
commonly prescribed for muscle cramps, controlled clinical 
trials of these drugs have reported mixed findings about 
efficacy. We investigated hydroquinine therapy in otherwise 
healthy adults who had frequent, ordinary muscle cramps.
Methods This randomised, double-blind, placebo-controlled, 
parallel-group trial consisted of three consecutive 2-week 
periods: qualification, treatment, and washout. 68 women 
and 44 men who had at least three muscie cramps per 
week were e n ro lle d . During th e  tre a tm e n t period, 
participants were randomly assigned 300 mg daily dose of 
hydroquinine hydrobromide dihydrate (54 participants) or 
placebo (58). The frequency, severity (1-10), duration, and 
location of muscle cramps, as well as any side-effects, 
were recorded by participants in daily diaries. The primary 
outcome measures were the number of muscle cramps and 
the number of days during which the partic ipants had 
muscle cramps (cramp-days).
Findings We excluded five participants from both groups 
from the analysis. Thus, data from 49 hydroqulnine-group 
partic ipan ts  and 53 placebo-group pa rtic ipan ts  were 
analysed. In both groups the to ta l number of muscle 
cramps and the number of cramp-days decreased during 
the trea tm ent period compared w ith  the qualification 
period. However, these improvements were greater in the 
hydroquin ine group than  in the  placebo group. The
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hydroquinine-group participants reported a median of 8 
(95% Cl 7-12) fewer cramps and median of 3 (1-4) fewer 
cramp-days, whereas those on placebo reported only 3 
(0 -5 )  fewer cramps and 1 (0-5) fewer cramp-days. 32 
(65%) of participants in the hydroquinine group had a 50% 
or greater reduction in the number of muscle cramps. After 
the onset of cramps, hydroquinine did not reduce the 
severity or duration of cramps. We also found a sustained 
effect after treatment had stopped. Hydroquinine was well 
tolerated, and resulted in only mild side-effects.
Interpretation In our study, 300 mg hydroquinine was safe 
to take in the short-term and significantly more effective 
than placebo in the prevention of frequent, ordinary muscle 
cramps. This therapeutic effect outlasted the duration of 
treatment.
Lancet 1997; 349: 528-32
Introduction
In  1988, a survey in the Netherlands reported that 36% of 
adults had  had  at least one muscle cramp in that year, and 
2% reported having weekly cramps.1 Surveys in the 
U K  and Switzerland gave similar findings.2-3 The 
pathophysiology of muscle cramp is little understood.4 
C u rre n t  evidence po in ts  to a distal origin in the 
intramuscular motor-nerve terminals.5
T he treatm ent of muscle cramps remains empiric, For 
m ore  th an  50 years, quinine and its derivatives, 
hydroqu in ine  and quinidine, have been commonly 
prescribed to prevent muscle cramps. These drugs exert 
a curare-like action on skeletal muscle and the 
neurom uscu lar  junction, b u t  the mechanism is not 
understood. Although quinine and derivatives are widely 
used, the clinical efficacy in muscle cramps is not yet 
established. Initial trials were uncontrolled and recent 
studies were small or of questionable design. In addition, 
potentially serious side-effects such as hypersensitivity
528 Vol 349 • February 22, 1997
TH E LANCET
r e a c t io n s  a n d  d o s e - r e l a t e d  cinchonism can occur/"10 
R e s o lu t io n  o f  these e f f ic a c y  and safety concerns are crucial 
for t h e  c o n t in u e d  u s e  o f  quinine derivatives for a benign 
in d ic a t io n  s u c h  a s  m u sc le  cramps. We conducted a 
r a n d o m i s e d  d o u b l e - b l i n d  parallel-group trial of 
h y d r o q u i n i n e  in a d ia l t s  w i th  frequent muscle cramps.
Methods
T h e  tria l w a s  c o n d u c t e d  b e tw een  October, 1993, and December, 
1994. W e r e c ru i te d  v o lu n te e rs  through notices in regional 
new spapers  a n d  p o s t e r s  in libraries and pharmacies. Eligible 
p a r tic ip an ts  w e re  t h o s e  aged 18 years or older who were in good 
general h e a l th ,  had a t  le a s t  th re e  muscle cramps per week during 
activity  or a t  r e s t ,  and  d i d  n o t take any medication for cramps. We 
defin ed  m u s c le  c ra m p  as a sudden, involuntary, painful muscle 
co n trac tio n  w h ich  w a s  accom panied by muscle hardening and 
lasted n o  l o n g e r  than. 10 m in ."  Muscle cramps are self-limiting 
and reso lve o v e r  s e c o n d s  to m inutes.12 We limited the maximum 
d u ra t io n  o f  a  muscle c r a m p  to  10 min to distinguish cramps from 
pain fu l m u s c l e  s tif fn ess .
Exclusion criteria w ere ;  a history of alcohol or drug use that 
would in te rfe re  with, participation; objection of the family 
physician to  t r e a tm e n t  w ith  hydroquinine; suspicion of 
contraindications or a llergy to hydroquinine; concurrent therapy 
with a drug th a t  m igh t interact with hydroquinine; pregnancy or 
lactation; a n d  lack of contraception in women of childbearing age.
A t e n r o lm e n t ,  v o lu n te e r s  were examined by a neurologist 
(P H P J)  to k e e p  to a m i n i m u m  the possibility that muscle cramps 
m ig h t be  a sy m p to m  o f  an underlying neuromuscular disease.
T h e  trial co n s is ted  of th re e  consecutive periods: a 2-week 
q u a lif ica tio n  periods d u r in g  which the baseline frequency of 
m u sc le  c r a m p s  was a s s e s s e d ;  a 2-wcek treatment period, during 
w hich  p a r t ic ip a n ts  w e r e  random ly  allocated hydroquinine or 
p laceb o ; a n d  a 2- w e e k  w ash o u t period, during which clinical 
after-effects  w e re  a s s e s s e d  a n d  the target symptoms allowed to 
re tu rn  to p r e  t r e a tm e n t  levels. We limited active treatment to
2 w eeks  in  a c c o r d a n c e  w ith  guidelines on the hydroquinine 
package  in s e r t .
T h e  trial w a s  c o n d u c te d  according to the European Guidelines 
for G o o d  C lin ica l R e s e a r c h  Practice and followed the 1983 
revised  p ro v is io n s  o f  the 1975 Declaration of Helsinki. The 
p ro to co l w a s  a p p ro v e d  by th e  ethics committee of our hospital. 
All p a r t i c ip a n t s  gave w r i t te n  informed consent to take part. In 
ad d itio n , t h e  p a r t i c ip a n t s 9 fam ily  physicians were asked to declare 
in w rit in g  t h a t  they d i d  not ob jec t to their patient’s participation.
Treatment  ’
W e u se d  a  s ta n d a rd  reg im en  of two 100 mg hydroquinine or 
p lacebo  t a b l e t s  to b e  taken with the evening meal plus one 
100 m g  h y d r o  qu in ine o r  p lacebo  tablet at bed-time. We asked the 
p a r t ic ip a n ts  t o  sw a llo w  the tab lets whole, without chewing them. 
P a r t ic ip a n ts  w ere g i v e n  an excess of medication and asked to 
re tu rn  the u n u s e d  t a b l e t s .  Com pliance was tested by comparison 
of th e  n u m b e r  of t a b l e t s  re tu rn ed  with the number prescribed.
W e  c h o s e  hydro q u i n i n e  hydrobromide dihydrate (Inhibin 
su g a r -c o a te d  tablets) b e c a u se  of availability; this compound is 
the o n ly  q u in in e  d e r iv a t iv e  registered in the Netherlands for the 
p rev en tio n  o f  m uscle c ra m p s .  Hydroquinine and placebo tablets 
were s u p p l i e d  in c o d e d  containers by the manufacturer (ASTA 
M e d ic a  B V , O iem en* N e th e r la n d s ) .
Random isation
T h e  h o s p i ta l  p h a rm a c is t s  received two coded containers, marked 
A a n d  B, h o ld in g  b o x e s  with hydro quinine or placebo tablets, and 
did n o t  k n o w  w hich  co n ta in e r  held the active treatment. An 
in d e p e n d e n t  in v e s t ig a to r  (T hdB ) used the random-number 
g e n e ra to r  o f  the S A .S  p rog ram  to create the randomisation 
schedu le . H e  s e p a ra te ly  assigned men and women to treatment in 
b locks o f f o u r .  We u s e d  separate  randomisation to avoid the 
p ro b le m  t h a t  had  a r i s e n  in th e  earlier pilot study, in which all the 
m en  h ad  b e e n  a s s ig n e d ,  b y  chance, to the placebo group.” 
R a n d o m is a t io n  in b l o c k s  was used to keep to a minimum possible
time effects. Thereafter, the in v e s tig a to r  linked the participants 
numbers to treatment A or B ac co rd in g  to the randomisation list, 
and marked the boxes with the  p a rtic ip an t number alone. 
Another investigator (KCWV) a ss ig n e d  consecutive participant s 
numbers to each individual p a r t ic ip a n t  in order of entry to th e
trial.
The hydroquinine and placebo tab le ts  were identical in  
appearance. All investigators i n v o l v e d  in the study and all 
participants were unaware of the t r e a tm e n t  allocation. D uring 
the trial, the randomisation code w a s  kept by the independent 
investigator (ThdB). The m a n u fa c tu r e r  kept the code fo r  
treatments A and B. At the end o f  t h e  trial, after all data w ere 
collected, the independent in v es tig a to r  disclosed the code o f  
randomisation. After the final a n a l y s i s ^  the  code for A and B w as 
revealed.
Outcome measures
The primary outcome measures w e r e  the number of muscle 
cramps and the number of days d u r in g  which the participant h a d  
muscle cramps (cramp-days). P a r t ic ip a n ts  used a daily diary to  
record the number, severity (on a s c a l e  o f  1 to 10), duration, a n d  
location of muscle cramps for the e n t i r e  6 weeks. We also asked 
participants to record in the diary a n y  possible side-effects o f  
treatment. The use of a daily diary t o  record muscle cramps h as  
been previously validated.13
Follow-up
We interviewed participants at e n ro lm e n t ,  before the treatm ent 
period (week 2), and after the t r e a tm e n t  period (week 5). D uring  
each interview, the participant’s d ia ry  w a s  reviewed and a history 
was taken (by KCWV) that focused o n  the clinical details of the  
muscle cramps. Participants were en co u rag ed  to describe th e ir  
symptoms and any side-effects.
Data from the participants’ d i a r i e s  and interviews w ere 
collected on standard forms, checked  fo r  accuracy, entered in to  
computer, and double-checked.
Statistical analyses
We calculated our sample size on th e  b a s is  of data from our p ilo t- 
study.13 We estimated that 38 p a r t ic ip a n ts  were required in each  
treatment group to give a power of 9 0 %  and a significance level o f  
0'05 in detecting a between-group difference of at least a 30%  
reduction in the number of muscle c r a m p s .
Although the minimum c l in ic a l ly  important differences 
(MCID) in the numbers of cramps a n d  cramp days between study 
periods and treatment groups may d i f f e r  with each individual, w e 
defined the MCID as a decrease of t w o  cramps per week and o n e  
cramp-day per week.
We used SAS software for the a n a ly s is .  The primary analysis o f  
the rate of treatment success—e x p re s s e d  as the decreases in th e  
number of muscle cramps and c ra m p -d a y s—was intention to treat, 
and included data from all s t u d y  periods for w hich  
end-of-period data were available.
Because most of the data did n o t  sa tisfy  a normal distribution, 
the results are given as die numbers o f  muscle cramps and cram p- 
days with median values and I Q R s .  Percentages were first 
calculated for each participant a n d  then the medians w ere  
calculated for treatment groups and s t u d y  periods.
The primary outcome measures w e r e  analysed by Wilcoxon’s 
signed-rank test for paired data a n d  W ilcoxon’s two-sample te s t 
for unpaired data. A two-sided p  v a lu e  of less than 0-05 w as 
considered significant. For the c o m p a r iso n  of data from d ie  
qualification and treatment periods5 d i a r y  entries for days 1 and 1 5 
were excluded because 15 particpants h a d  not made a diary entry  
on day 1, had not taken their first d o s e  of medication until th e  
evening of day 15, or both. To h a v e  equal study periods for th e  
qualification and washout periods, d i a r y  entries for days 1,13, 14, 
29, 41, and 42 were excluded f ro m  th e  analysis because seven 
participants had not completed the ir  d ia ry  entries on day 1, or o n  
days 41 and 42, or both. The in d iv id u a l effects o f potential 
confounding factors, such as age a n d  body-mass index, w ere 
analysed by stepwise regression.
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Hydroqulnlne group Placebo group
(n=49) (n=53)
Sex (m/f) 18/31 20/33
Age on July 7,1994 (years) 54(20-77) 47 (17-87)
Height (cm) 172 (154-196) 173(158-190)
Bodywelght (kg) 74(46-113) 72 (56-108)
Smoking
Current smokers 13(27%) 15 ( 28%)
Number of cigarettes per day 10 ( 3-40) 15 ( 1-25)
Alcohol Intake
Drinkers 26{53%) 26 (49%)
Number of drinks per week 5-5 (1-32) 10 {1-35)
History of muscle cramps (years)
<1 2 ( 4%) 2 {4%)
1-5 15 ( 31%) 13(25%)
5-10 9 ( 18%) 11(21%)
>10 19 ( 39%) 27 (51%)
Tonic water intake
1 glass per week 1 ( 2%) 1(2%)
2 glasses per week 3 ( 6%) 1 ( 2%)
Previous sciatica
Yes 8 ( 16%) 16 ( 30%)
No 41(84%) 37(70%)
Muscle cramps
Duration (min) 1-5 (0'3-6*l) 1*7 (0-1—5'5)
Severity (numerical scale 0-10) 4*6 (1-6-8-8) 4'l(l-5-8<4)
Values are median (IQR).
Table 1: Baseline characteristics of participants
Results
382 volunteers responded to the recruitment notices and 
posters. O f these responders, 270 were excluded because 
they did no t fulfil the inclusion criteria or met one 
or more of the exclusion criteria. Thus* 112 volunteers 
were enrolled, 54 participants (34 women and 20 men) 
were random ly assigned to  hydroqu in ine , and  58 
(34 women and 24 men) to placebo (figure 1). T he  two 
groups were well m atched  in baseline characteristics 
(table 1).
Of the 112 participants* 101 completed the trial. During 
the qualification period, six participants were withdrawn 
because of failure to practise contraception (one woman in 
hydroquinine group), only one muscle cramp reported 
during  the qualifica tion  p e r io d  (one w om an in 
hydroquinine group), and inability to comply with the 
guidelines for diary-keepjng (two in hydro quinine group 
and two in placebo group). D uring the treatm ent period, 
five participants were withdrawn. T rea tm en t was stopped 
because of side-effects in one w om an and two m en in the 
placebo group and in one w om an in the hydroquinine 
group. One m an in the placebo group, who had a history 
of sporadic gout attacks, was withdrawn from the study 
because he required concurrent analgesic medication. Of 
these five drop-outs, the w om an in the hydroquinine 
group and two placebo-group participants had sufficient 
data, assuming unchanged m ean  cramp frequency, to 
allow extrapolation to the end of the treatm ent period (day 
28). There were no drop-outs during the washout period, 
although two participants were excluded after this period 
because they did no t have complete diary records. Thus, 
data from 49 participants in the hydroquinine group and 
53 placebo-group partic ipants were included in the 
in ten tion -to -trea t analysis o f  th e  qualification and 
treatment periods (figure 1). D ata  from one m an were 
omitted because he becam e ill during the washout period 
and reported a substantial increase in frequency of cramp. 
Data from 98 participants (47 hydroquinine, 51 placebo)
Figure 1: Trial profile
were included in the comparison of the qualification and 
washout periods,
Compliance was good (>90% pills taken) and the 
num ber of returned tablets did not differ significantly 
betw een the hydroquinine and placebo groups: 47 
participants (98% )3 and  51 participants (100%)j 
respectively.
Table 2 shows the between-group differences in the 
median num ber of cramps and cramp-days during the 
study periods. During the treatment period, the median 
difference in the num ber of cramps and cramp-days 
between the hydroquinine and placebo groups was 
5 (95% C l 2-8) and 1 (0—3), respectively.
Study period Hydroquinine
group
Placebo
group
Median 
difference 
(95% Cl)
Qualification
Number of participants
Cramps
Cramp-days
49
17 (10-31) 
8(7-12)
53
17(10-22) 
8(7-11)
-1  ( -6  to 3) 
0 ( -1  to 1)
Treatment
Number of participants
Cramps
Cramp-days
49 
7 (4-11) 
5(3-7)
53
13 (6-18) 
7(4-10)
5 (2 to 8) 
1 (0 to 3)
Washout
Number of participants
Cramps
Cramp-days
47 
9(5-17) 
6(4-9)
51
8(5-22) 
5(3-8)
-1  ( -4  to 3) 
-1  ( -2  to 0)
Number of cramps and cramp-days are median (IQR).
Table 2: Number of cramps and cramp-days during 
qualification, treatment, and washout periods
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Figure 2: Percentage decrease in number of muscle cramps In 
hydroquinine and placebo groups during treatment period
m
Figure 2 shows the percentage decrease in the num ber 
of muscle cramps during the treatm ent period between 
hydro quinine and placebo groups: 37 (76%) vs 25 (47%) 
had a 25% decrease; 32 (65%) vs 10 (19%) had a 50% 
decrease; and 15 (31%) vs 3 (6%) had  a 75% decrease.
The proportions of men and women with reductions in 
the number of muscle cramps from the start of the 
qualification to the end of the treatm ent period were 
*
similar in both groups (p^O'S in hydroquinine group3 
p=0*7 in placebo group).
Differences in severity and duration of muscle cramps 
between the two groups were small and  did not achieve 
significance (p>0*l). Similarly, in both groups* differences 
in severity and duration of muscle cramps between the 
qualification and the  trea tm ent periods were not 
significant (p>0*l).
Stepwise regression of the data from the hydro quinine 
group showed that body height and body-mass index had 
a significant effect on response (p<0*01). A body-mass 
►
index of more than 25 kg/m2 was associated with a greater 
percentage decrease in the number of cramps., whereas 
body height was negatively correlated to the percentage 
decrease in the num ber of cramps.
Table 3 shows the side-effects in both  groups. T h e  only 
side-effect definitely related to hydro quinine was a bitter
Side-effects Hydroquinine 
group (n=49)
Placebo 
group {n=53)
Definitely hydroquinine-related
Bitter taste, dry mouth 10 ( 20%) 0
Tinnitus 1(2%) 0
Possibly hydroquinlne-reiated
Nausea, vomiting 7 ( 14%) 4(8%)
Headache 5 ( 10%) 3(6%)
Dizziness 3 ( 6%) 5(9%)
Diarrhoea, abnormal stool 3(6%) 1(2%)
Unrest, perspiration, tremor 2(4%) 0
Itching, blushing 2 ( 4%) 0
Visual complaints 1 ( 2%) 0
Irregular heartbeat 1 ( 2%) 0
Bleeding gums 1(2%) 0
Not hydroquinine-related
Musculoskeletal pain 3(6%) 3(6%)
Fatigue, somnolence 2 ( 4%) 0
Muscular twitching, stiffness 1 ( 2%) 1 ( 2%)
Swollen joint 0 1 ( 2%)
Cough 1(2%) 0
taste or dry m outh  (ten participants) and one case of 
tinnitus. There were no significant differences in age> sex3 
compliance* or percentage decrease in median num ber of 
muscle cramps between participants who reported side- 
effects and those who did not. However* hydroquinine- 
group participants who reported side-effects were slightly 
heavier than those who did no t (mean body weight 80 [15] 
vs 70 kg [11]* respectively)* and also had a higher body- 
mass index (26-8 [4*5] 23*8 kg/m2 [3-8]).
Table 3: Side-effects
Discussion
A crossover design is suitable for drugs with effects that 
fade rapidly after treatm ent has been stopped. The effects 
of drugs such as quinine and hydro quinine may outlast 
their administration by at least a week*13 thus* a crossover 
design would be inapropriate unless an adequate washout 
is scheduled  before crossover. D u n n 14 reported  a 
significant carryover effect of quinine for night cramps. 
Hing and WelFs meta-analysis15 o f  six small crossover 
trials concluded that treatm ent with quinine for 4 weeks 
resulted in a significant reduction in the num ber of 
nocturnal leg cramps and nights with cramps compared 
with placebo. However* a m eta-analysis canno t be 
considered as a substitute for a large* well-designed* and 
carefully conducted trial.16,17
A parallel-group trial may* therefore* be preferable to 
assess the effects of quinine and its derivatives in 
individuals with muscle cramps. There  have only been two 
parallel-group trials of quinine for m uscle cramps. 
Gorlich's study18 was designed to investigate a possible 
improvement in the effects of quinine by theophylline 
ethylene diamine. Our previous study13 was able to assess 
the effects of hydro quinine only in women because of an 
unlucky randomisation procedure.
In  our parallel-group trial in otherwise healthy adults 
with frequent ordinary muscle cramps* the low confidence 
limits we found for the total decrease in the median 
num ber of cramps (eight cramps) and cramp-days (three 
cramp-days) in the hydroquinine group are clinically 
relevant (table 2). A lthough bo th  hydroquinine and 
placebo significantly reduced the num ber of muscle 
cramps and cramp-days* the improvement was greater in 
hydroquinine-group participants, 32 (65%) participants 
in the hydroquinine group* compared with only 10 (19%) 
placebo-group participants* had  a 50%  or greater 
reduction in the num ber of muscle cramps.
T he perceived placebo effect in the placebo group was 
equivalent to a mean percentage decrease o f  14% in the 
number of muscle cramps. Subtraction o f this placebo 
effect from the treatment effect in the hydroquinine group 
(50%) yields a 36% m ean percentage decrease in the 
num ber of muscle cramps. Thus* the effect of 
hydroquinine was almost three times greater than that of 
placebo.
We did no t find any significant changes in the estimated 
duration and severity of cramps between the groups. This 
finding may be because these variables are more subjective 
and difficult to quantify than* for example* the num ber of 
cramps* and thus only large differences will be observable. 
This finding accords with data  repo rted  in earlier 
crossover trials.15,19
O ur finding that ten participants complained of a bitter 
taste 'during hydro quinine therapy raises the question of 
w hether these individuals were aware of trea tm en t 
allocation. D uring the design of the trial* it proved to be
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technically unfeasible to produce a placebo with a bitter 
taste. However, participants were presumably unaware of 
this property of hydro quinine and were unable to compare 
the taste of active medication with tha t of placebo. 
Furthermore, since the hydroquinine tablets were sugar- 
coated and subjects were to ld  to swallow the tablet whole, 
any bitter taste would have been perceived only after drug 
absorption. Thus, we believe tha t any difference in taste 
between hydro quinine and  placebo was unlikely to have 
biased participants* reporting of treatm ent effects.
Several studies point to increased quinine efficacy with a 
longer duration of therapy, and suggest tha t it may be 
necessary to administer quinine for 4 weeks to achieve 
optim um  therapeutic  benefits .15,18-20 Nevertheless, the 
2-week treatm ent period in our study was long enough to 
confirm the clinical efficacy o f  hydroquinine/
In Connolly and colie agues’ s tudy ,19 500 mg quinine 
daily resulted in a 50% or greater reduction in the num ber 
of muscle cramps in 13 (48%) of 27 men. By contrast, we 
obtained a 65% response rate with a standard daily 
regimen of 300 mg hydro quinine. Variability between 
individuals may result from differences in bio availability 
and drug a b so rp t io n .13 T h u s ,  the benefits of 
(hydro) quinine therapy m ight be improved by monitoring 
drug levels.
In this study, we found tha t during the washout period 
participants in both groups recorded sustained percentage 
decreases in  the n u m b e r  o f  cram ps. Cessation of 
(hydro)quinine therapy m ay be followed by sustained 
relief from muscle cramps* even for several m onths.13 This 
clinical after-effect may be responsible for carryover effects 
in crossover trials that do not have a sufficiently long 
washout before crossover. Furtherm ore, because of the 
duration of the after-effect and our observation that 
placebo as well as active trea tm ent had  beneficial effects 
that outlasted administration, it is questionable whether 
this clinical after-effect reflects a pharmacological action.
O ur findings are consistent with the hypothesis that 
relief from frequent muscle cramps in itself may prevent 
the recurrence of cramps by a physiological mechanism 
that interrupts the cycle of cramps. After a cramp, delayed 
localised soreness does no t usually appear for 24-48 h and 
is accompanied by involuntary tonic muscle-spasm, which 
could precip ita te  an o th e r  cram p by  m echanical or 
chemical irritation.21 Irrespective of the mechanism of 
sustained relief o f  c ram ps, it seem s reasonable  to 
exploit this effect in clinical practice by interrupting 
(hydro) quinine treatm ent.
T h e  benefits of hydroquinine should be weighed against 
the risk of side-effects. Previous trials reported only mild 
side-effects associated with quinine derivatives. H ing and 
Wells5 meta-analysis15 reported that only one o f 107 
participants in six studies h ad  serious side-effects (nausea, 
myalgia, leucopenia , an d  th rom bocy topen ia ) , which 
resolved 3 days after treatm ent had  stopped. In  our study5 
hydroquinine was well tolerated by  m ost participants: only
11 reported mild side-effects. Hydroquinine-related side- 
effects (bitter taste, nausea) necessitated cessation of 
treatm ent in only one participant.
W e do not know why body height and body-mass index 
em erged as explanatory  variables in  the  stepwise 
regression analysis. A body-mass index o f more than
25 kg/m2 was associated with a greater therapeutic effect at 
the cost of increased side-effects; it is unlikely that this 
finding can be attributed to  storage of hydroquinine or 
metabolites in body fat or fluids. Studies are needed to 
assess whether dose adjustments according to body-weight 
or body surface area are warranted.
In conclusion, the results of this study confirmed that a 
daily dose of 300 mg hydroquinine dihydrate is safe to 
take on a short-term basis, and is significantly more 
effective than placebo in the prevention of frequent, 
ordinary muscle cramps in otherwise healthy adults. 
Because hydroquinine did not ameliorate the severity or 
duration of muscle cramps once they had occurred, we 
believe that the drug should be prescribed on a regular 
rather than on an as-needed basis.
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